• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

14
14
14
5

COUNTRY

14

CATEGORIES

  • 25
  • 5
  • 3
  • 3
  • 2
  • 1

PRICE

5
29
30
38

PUBLISHED

0
3
5
38

PRODUCT TYPE

21
11
6

Search "BioMarin Pharmaceutical Inc-Deals & Alliances Report" returned 38 results.

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis,...

November 2013
FROM

BioMarin Pharmaceutical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain...

May 2015
FROM

Pharma and Biotech M&A Trends 2009-2014 [old name Merger & Acquisition Terms and Agreements]

The Pharma and Biotech M&A Trends 2009-2014 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma...

July 2014
FROM
BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011 BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011 - Product Thumbnail Image

BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011

BioMarin Pharmaceutical Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011” provides...

November 2011
FROM

Gene Therapy Partnering Terms and Agreements (3rd Edition)

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

December 2014
FROM

Antibiotics Partnering Terms and Agreements

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

December 2013
FROM

Myelodysplastic Syndrome - Pipeline Review, H1 2014

Myelodysplastic Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Myelodysplastic Syndrome - Pipeline Review, H1 2014’, provides an overview of the Myelodysplastic Syndrome’s therapeutic...

February 2014
FROM
Orphan Drugs - Global Strategic Business Report Orphan Drugs - Global Strategic Business Report - Product Thumbnail Image

Orphan Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts...

April 2015
FROM

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review,...

February 2014
FROM
Myelodysplastic Syndrome - Pipeline Review, H2 2012 Myelodysplastic Syndrome - Pipeline Review, H2 2012 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H2 2012

Myelodysplastic Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H2 2012', provides an overview of the Myelodysplastic Syndrome therapeutic...

August 2012
FROM

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

May 2015
FROM
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012 - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review,...

August 2012
FROM

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

June 2015
FROM
Myelodysplastic Syndrome - Pipeline Review, H1 2012 Myelodysplastic Syndrome - Pipeline Review, H1 2012 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H1 2012

Myelodysplastic Syndrome – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H1 2012', provides an overview of the Myelodysplastic Syndrome therapeutic...

January 2012
FROM
Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011 Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011 - Product Thumbnail Image

Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011

Daiichi Sankyo Company, Ltd – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011” provides data...

November 2011
FROM

Industry Report Card: Ratings Outlook Remains Stable For U.S. For-Profit Health Care Companies May 12

Abstract Standard & Poor's Ratings Services expects ratings for 2012 on the U.S. for-profit health care sector to be stable. Our view reflects adequate or better liquidity for a high majority of issuers,...

May 2012
Leukemias - Pipeline Review, H1 2012 Leukemias - Pipeline Review, H1 2012 - Product Thumbnail Image

Leukemias - Pipeline Review, H1 2012

Leukemias – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2012', provides an overview of the Leukemias therapeutic pipeline. This report provides information...

January 2012
FROM

Industry Report Card: Medicare Cuts Loom As A Senior Factor in U.S. Health Care Company Ratings Oct 11

Abstract Third-party funding of essential care, along with continued high margins for patented medical treatments, has protected many U.S. for-profit health care industry participants from the difficulties...

October 2011

Industry Report Card: The 2011 Credit Prognosis For U.S. Health Care Companies Generally Is Favorable Jan 11

Abstract The prospect for an extended mid-single-digit revenue rise in U.S. health spending remains intact for 2011, based on the ongoing need for largely essential medical goods and services. According...

January 2011

Industry Report Card: A Rash Of Activity For U.S. Speculative-Grade Health Care Companies Jul 10

Abstract With near-term industry visibility improving in the first half of 2010, yield-hungry investors appear to have an increasing interest in the sector's speculative-grade debt issuers. Consequently,...

July 2010
Loading Indicator

Our Clients

Credit Suisse Group Heinz Company Telenor Group Deutsche Bank AG Solvay S.A. APC by Schneider Electric Lindt & Sprüngli AG